Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASTX660 in Relapsed or Refractory T-Cell Lymphoma (Phase I/II, Japan)
jRCT2080225162Phase 2Completed
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tolinapant in non-Hodgkin lymphoma, T-cell, peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL), sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoints: Tolerability of ASTX660, Safety of ASTX660 and 1 more. Started Apr 2020; status: completed.
02
Drugs
tolinapant
03
Conditions
non-Hodgkin lymphoma, T-cellperipheral T-cell lymphoma (PTCL)cutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on jRCT2080225162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225162.